ULURU Inc. Sponsors Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference (DFCon)

ADDISON, Texas, March 23 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Amex: ULU) announced that it sponsored a Wound Dressing Workshop at the 2010 Diabetic Foot Global Conference. Attendees of the Diabetic Foot Global Conference (DFCon) in Hollywood, California on March 20, 2010 participated in a hands-on workshop where they were trained in "best clinical practice" for Altrazeal™. Participants learned application techniques, clinical endpoints, and methods for treating different wound types including diabetic foot ulcers, venous stasis ulcers and pressure ulcers. The workshop was led by Dr. John Steinberg, DPM of Georgetown University Hospital.

DFCon is the leading diabetic foot ulcer conference featuring state-of-the-art concepts in wound healing. This conference was attended by world-renowned clinicians specializing in the management and treatment of diabetic foot ulcers. ULURU also had a booth presence at the meeting where Altrazeal™ was demonstrated to the conference attendees.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "Our active participation at DFCon is the start of an exciting period of high profile, nationally recognized wound care conferences where Altrazeal™ will receive great visibility. These conferences allow us to showcase the exciting clinical data on Altrazeal™ that has been generated in the treatment of chronic wounds, including diabetic foot ulcers, venous and pressure ulcers".

About DFCon:

DFCon is the premier international interdisciplinary diabetic foot conference in North America. This year's conference was sponsored by Valley Presbyterian Hospital in cooperation with International Conference Management, Inc. It featured the presentation of the 7th Annual Edward James Olmos Award for Advocacy in Amputation Prevention. Featuring a world-renowned faculty, it offers the opportunity to review state-of-the-art concepts and techniques. For more information please visit: www.DFCon.com.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex™ Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, and suitability of Altrazeal™, and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and quarterly report on Form 10-Q for the quarter ended September 30, 2009, and other reports filed by us with the Securities and Exchange Commission.

SOURCE ULURU Inc.